Skip to main content
. 2023 Sep 2;14:5360. doi: 10.1038/s41467-023-41177-x

Fig. 3. Supplementation with recombinant FAM3A protein in the AngII-ApoE−/− murine AAA model ameliorates pathological outcomes.

Fig. 3

a Schematic diagram of recombinant FAM3A intravenous injection in AngII-ApoE−/− murine AAA models. b Quantification of blood pressure is shown from mice treated as in a (n = 6 biologically independent animals; *P < 0.05, ***P < 0.0001 AngII + PBS group versus Saline + PBS group). c Representative echocardiographic images and quantification of diameters of abdominal aorta from mice treated as in (a) (n = 8 biologically independent animals). d Kaplan–Meier curve and log-rank test showed the survival probability from mice treated as in (a) (n = 20 biologically independent animals). e ELISAs were used to evaluate the plasma inflammatory factors from mice treated as in (a) (n = 8 biologically independent animals). f Representative western blot images and quantification of MMPs and VSMC contractile marker proteins are shown in aortas from mice treated as in (a) (n = 6 biologically independent animals; quantitative comparisons between samples were run on the same gel). Data are presented as mean ± SEM (b, c, e, f) and mean±95% CI (d). Statistical significance was calculated with one-way ANOVA followed by Tukey post hoc test (b, c, e), Kaplan–Meier analysis and log-rank test (d), and two-tailed independent t test (f), and P values are indicated (*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). Source data are provided as a Source Data file.